Acute myeloid leukaemia with myelodysplasia-related features

Get in touch with RARE Concierge.

Contact RARE Concierge

Acute myeloid leukaemia with myelodysplasia-related features

Synonyms: AML with multilineage dysplasia | AML with myelodysplasia-related features | Acute myeloid leukemia with multilineage dysplasia

A rare acute myeloid leukemia (AML) characterized by the presence of acute leukemia with at least 20% peripheral blood or bone marrow blasts with morphological features of myelodysplasia or occurrence in patients with a prior history of a myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm with MDS-related cytogenetic abnormalities in the absence of specific genetic abnormalities characteristic of AML with recurrent genetic abnormalities. Prior cytotoxic or radiation therapy for an unrelated disease must be excluded. The condition occurs mainly in elderly patients and is rare in children. Patients often present with severe pancytopenia. Prognosis is generally poor.

Data from Orphanet are used to provide information on a disease's name, synonym(s), and overview.

Reference: Access aggregated data from Orphanet at Orphadata.

Orphadata: Free access data from Orphanet. © INSERM 1999. Available on http://www.orphadata.org. Data version February 2024

Newly diagnosed with
Acute myeloid leukaemia with myelodysplasia-related features?

Our RARE Concierge Services Guides are available to assist you by providing information, resources and connections as you navigate your rare disease journey.

Get Concierge Help

Advocacy Organizations

Team Telomere

A Community for Telomere Biology Disorders Our mission is to provide information and support services to families worldwide affected by Dyskeratosis Congenita and Telomere Biology Disorders, to encourage the medical community’s research in finding causes and effective treatments, and to facilitate improved diagnosis by educating medical providers.

Clinical Trials

For a list of clinical trials in this disease area, please click here.